CN106190980A - A kind of special culture media and cultural method being used for In vitro culture esophageal carcinoma tumor organoid based on Human Esophageal Carcinoma - Google Patents
A kind of special culture media and cultural method being used for In vitro culture esophageal carcinoma tumor organoid based on Human Esophageal Carcinoma Download PDFInfo
- Publication number
- CN106190980A CN106190980A CN201610548084.1A CN201610548084A CN106190980A CN 106190980 A CN106190980 A CN 106190980A CN 201610548084 A CN201610548084 A CN 201610548084A CN 106190980 A CN106190980 A CN 106190980A
- Authority
- CN
- China
- Prior art keywords
- esophageal carcinoma
- cell
- human
- culture
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/12—Hepatocyte growth factor [HGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/80—Neurotransmitters; Neurohormones
- C12N2501/81—Adrenaline
Abstract
The present invention relates to the cultivation field of tumor organoid, be specifically related to a kind of based on Human Esophageal Carcinoma for the special culture media of In vitro culture esophageal carcinoma tumor organoid and cultural method.Described special culture media includes the agonist of the path of FZ inhibitors of kinases, Metabolism, Vitamins and Hormones, antioxidant and the differentiation of suppression cell that receptor tyrosine kinase part, Rho are relevant.The substep culture technique that the present invention is dedifferented by condition, it is achieved in the tumor cell short time, rapid amplifying becomes organoid.Technology that this substep is cultivated makes primary cell can quickly form organoid, and obtains abundant cell within the time effectively and carry out subsequent experimental operation, improves cultivation speed and the success rate of organoid.
Description
Technical field
The present invention relates to the cultivation field of tumor organoid, be specifically related to one based on Human Esophageal Carcinoma for external training
Support special culture media and the cultural method of esophageal carcinoma tumor organoid.
Background technology
The esophageal carcinoma is common malignant tumor of digestive tract, accounts for the 2% of all malignant tumor.The whole world there are about 20～30 every year
Ten thousand people die from the esophageal carcinoma.The esophageal carcinoma should ranked first position in China's digestive system tumor, position in whole tumor sorts
Secondary the highest, about 45 levels.Compared with other countries, the Incidence of esophageal cancer of China is that comparison is high, the whole world nearly one
The esophageal carcinoma of half occurs in China.China is Incidence of esophageal cancer and the highest country of mortality rate, annual Incidence of Esophageal Cancer and dead
Number of dying all account for the whole world number more than half.Visible, the esophageal carcinoma can be considered one of malignant tumor of most distinct Chinese characteristics.Esophagus
The morbidity of cancer is relevant with E&H factor, but exact cause and pathogenesis are not clear.With gastric cancer, hepatocarcinoma is similar to, by
Relatively low in Hesperian sickness rate, cause the tumor occurred frequently compared with other wests of studying of the esophageal carcinoma in world wide to fall
After.And the highest as China's incidence rate, one of several tumors that fatality rate is the highest, strengthen study of pathogenesis and the medicine of the esophageal carcinoma
Thing research and development have very major and immediate significance.
Existing esophageal carcinoma cell line is mainly by long-term cultivation, and spontaneous immortalization or transfection promote normal cell immortality
The oncogene changed obtains.Such as Het-1A is that a strain is resisted by people's normal esophageal epithelial cell, the big T viral by transfection Sv40
Former, make cell obtain immortalization and obtain.These methods change the genetic background of cell, the cell line of long-term cultivation, also hold
Easily cause genomic instability, may cause the phenotype of tumor cell line and interior tumor cell that artificial change, impact occur
Esophageal carcinoma scientific research and the accuracy of medicine method research and development.
Esophageal carcinoma original cuiture pattern before, after tumor cell and other cell separation, plants in Tissue Culture Dish
In, cell loses original microenvironment.Therefore cell is difficult to steady in a long-term cultivation.Therefore, tumor growth is simulated in vitro
Microenvironment, it is provided that the three-dimensional that tumor is depended on for existence supports and multiple existence path, it is possible to realize training the most steady in a long-term
Support tumor tissues.
The cultivation of vitro in primary tumor cell organoid, it is desirable to provide simulation tumor microenvironment in vivo.These micro-loop
Border includes maintaining the extracellular matrix of 3 D stereo cultivation conditions, the somatomedin of important path of surviving, suppression cell to divide
The factor changed, various vitamin, trace element, hormone, energy metabolism, Antioxidative Factors, fine chemical synchronizing signal and anti-
Tune is died material.Each tumor type, even not same tumor cell hypotype, these microenvironment factors all may differ widely,
Therefore, the cell primary organoid of different tumor types is cultivated, and is required for the type of this tumor, optimizes one by one.
Original organoid culture technique is applied to the cultivation of human esophagus cancer organoid following problem: first generation incubation time is relatively
Long, need just to complete the first generation 2 to 6 weeks and cultivate；The vigor passing on rear organoid declines rapidly, and the speed of growth substantially slows down；
Frozen rear recovery efficiency is low, and easily dead, vigor reduces, and the speed of growth slows down；The success rate cultivated is the highest, and it is new that operation obtains
Fresh insufficient sample 60%；For biopsy specimen, original organoid culture technique almost cannot effectively be cultivated.
The tumor organoid of esophageal cancer cell is cultivated, and makes on the conditioned basic that mice and human stem cell organoid are cultivated,
In conjunction with the feature of esophageal cancer cell, further optimal conditions, to utilize less tissue, within the shorter time, it is thus achieved that more preferably
Cell viability and higher success rate.
Summary of the invention
Present invention aim to address above-mentioned the deficiencies in the prior art, it is provided that one is used for external based on Human Esophageal Carcinoma
Cultivate special culture media and the cultural method of esophageal carcinoma tumor organoid.
The present invention is achieved by the following technical solutions:
A kind of special culture media being used for In vitro culture esophageal carcinoma tumor organoid based on Human Esophageal Carcinoma, described special
Culture medium includes following components:
(1) receptor tyrosine kinase part,
(2) FZ kinases (ROCK1, ROCK2) inhibitor relevant for Rho,
(3) Metabolism, Vitamins and Hormones,
(4) antioxidant,
(5) agonist of the path of suppression cell differentiation.
Preferably, described receptor tyrosine kinase part include the epithelical cell growth factor (EGF) of human or animal, people or
One or more in animal liver cell somatomedin (HGF) and human or animal's basic fibroblast growth factor (bFGF).
Preferably, described
The concentration range of the epithelical cell growth factor of human or animal is 2ng/mL～100ng/mL；
The concentration range of human or animal's hepatocyte growth factor is 10ng/mL～200ng/mL；
The concentration range of human or animal's basic fibroblast growth factor is 5ng/mL～100ng/mL.
Preferably, relevant for described Rho FZ inhibitors of kinases include Fasudil, Y-27632, RKI-1447 and
One or more in GSK429286A.
Preferably, during described Metabolism, Vitamins and Hormones includes putrescine, Adrenalone, nicotiamide and vitamin A acetate
Plant or multiple.
Preferably, described
The concentration range of putrescine is 0.1 μ g/mL～100 μ g/mL；
The concentration range of Adrenalone is 10ng/mL～10 μ g/mL；
The concentration range of nicotiamide is 1 μ g/mL～2mg/mL；
The concentration range of vitamin A acetate is at 10ng/mL～500ng/mL.
Preferably, described antioxidant includes reduced glutathion (GSH), vitamin C, vitamin E and β-sulfydryl second
One or more in alcohol.
Preferably, the concentration range of described beta-mercaptoethanol is 0.01mM～1.5mM.
Preferably, the agonist of path of described suppression cell differentiation include people's activin A albumen, Wnt pathway agonist,
One or more in Hedgehog pathway agonist.
Preferably, described
The concentration range of people's activin A (activin A) albumen is 5ng/mL～200ng/mL；
Wnt pathway agonist includes recombinate the Wnt3a albumen of human or animal, restructuring human or animal's RSPO-1 albumen, GSK-3
One or more in beta inhibitor；
Hedgehog pathway agonist includes human or animal's SHH albumen of recombinating, the one in the agonist SAG of SMO albumen
Or it is multiple.
Preferably, described special culture media includes following components:
ECRM-I:DMEM/F12 culture medium, adds 2.5% hyclone (FBS), 1x B27 additive, ascorbic acid, dimension
Raw element A acetate, Adrenalone, putrescine, nicotiamide, insulin, hydrocortisone, people's activin A, FGF2, Wnt3a, EGF,
Tretinoin and Y27632；Or
ECRM-II:DMEM/F12 culture medium, adds 2.5% hyclone, 1x B27 additive, nicotiamide, adrenal gland
Ketone, BMP4, EGF, Wnt3a, IGF, sodium butyrate, putrescine, vitamin A acetate, insulin, dexamethasone, beta-mercaptoethanol,
FGF2, people's activin A, tretinoin and Y27632；Or
ECRM-III:DMEM/F12 culture medium, adds 1% bovine serum albumin (BSA), 1x B27 additive, peroxidating
Hydrogen is mould, vitamin A acetate, nicotiamide, Adrenalone, sodium butyrate, insulin, dexamethasone, putrescine, reduced form gluathione
Peptide, people's activin A, EGF, BMP4, FGF1, NOG, SAG, RSPO1, Wnt3a and Y27632；Or
EDM-1:DMEM/F12 culture medium, add 2.5% hyclone, 1x B27 additive, HGF, IGF, Wnt3a,
EGF, people's activin A, Adrenalone, vitamin A acetate, nicotiamide, insulin, reduced glutathion.
A kind of training utilizing the special culture media being used for In vitro culture esophageal carcinoma tumor organoid based on Human Esophageal Carcinoma
Breeding method, comprises the following steps:
(1) by the esophageal carcinoma specimen tissue of fresh acquisition, clean with tissue-wash solution；
(2) once purged esophageal carcinoma specimen tissue is transferred in tissue transfer liquid, is placed in 0 to 4 degrees Celsius of transfers or short
Phase preserves；
(3) from tissue transfer liquid, take out piece of tissue, in tissue-wash solution after rinsing, transfer to steril cell culture dish
In, sop up surplus liquid；
(4) according to the size of piece of tissue, add tissue digestion liquid, cut with sterilizing and repeatedly shred tissue；
(5) tissue shredded is transferred in sterile centrifugation tube, continuously add 2～10mL tissue digestion liquid, clean transfer
Tumor tissues in culture dish, is incorporated in sterile centrifugation tube；
(6) sterile centrifugation tube being placed in 37 degrees Celsius of shaking tables digestion, frequently take out observation, how digestion is to few cell mass
Or till unicellular；
(7) by the suspension in sterile centrifugation tube through 70 μm cell screen clothes, filtered solution is transferred in 50mL centrifuge tube；
(8) adding 10～30mL PBS in 50mL centrifuge tube, 100～300g are centrifuged 2～5 minutes, abandon supernatant, with 10～
30mL PBS is resuspended, again 100～300g is centrifuged 2～5 minutes；
(9) suck the supernatant in centrifuge tube carefully, add the special culture media of 3～8mL esophageal carcinoma tumor organoids,
Re-suspended cell；
(10) take 50～200 μ L cell suspension and add trypan blue, calculate the quantity of living cells by platelet counter；
(11) it is close that the special culture media of the cell suspension esophageal carcinoma tumor organoid after counting carries out resuspended adjustment cell
Degree, adds the Matrigel of 4 DEG C of defrostings of cell suspension 0.1 to 1 times；
(12), after cell suspension is resuspended with Matrigel, it is inoculated in 24 orifice plates, is placed in 37 DEG C of cell culture incubators, 15～30
After minute, treat that Matrigel solidifies, add the special culture media of esophageal carcinoma tumor organoid, change liquid every other day；
After (13) 4～10 days, esophageal carcinoma organoid grows up to many spheroid forms, has epithelioid cell layer.
Preferably, the compound method of step (1) and (3) described tissue-wash solution is: in normal saline or phosphate-buffered
Liquid adds the penicillin of 500U/mL, the amphotericin B of 2.5 μ g/mL and the streptomycin of 500 μ g/mL, filtration sterilization.
Preferably, the compound method of step (2) described tissue transfer liquid is: add 5% tire Sanguis Bovis seu Bubali in DMEM culture medium
Clearly, the penicillin of 500U/mL, the amphotericin B of 2.5 μ g/mL and the streptomycin of 500 μ g/mL are added.
Preferably, the compound method of step (4) and (5) described tissue digestion liquid is:
EM-BS-1: add 2.5% hyclone, 1 μ g/mL～the IX Collagen Type VI of 10 μ g/mL, 50 μ in DMEM culture medium
The neutral proteolytic enzyme of g/mL-500 μ g/mL；Or
EM-BS-2: add 2.5% hyclone, 1x penicillin and streptomycin, 0.01mg/mL-in DMEM culture medium
The IV Collagenase Type of 1mg/mL, the hyaluronidase of 0.001mg/mL～0.2mg/mL and 0.001mg/mL's～0.2mg/mL
DNA enzymatic I；Or
EM-3: add 2.5% hyclone, 1x penicillin and streptomycin, 20U/mL～200U/mL in DMEM culture medium
The DNA of Bacillus polymyxa Neutral proteinase neutral proteolytic enzyme I and 0.01mg/mL～1mg/mL of XI Collagenase Type, 1 μ g/mL～100 μ g/mL
Enzyme I.
The beneficial effects of the present invention is:
The substep culture technique that the present invention is dedifferented by condition, it is achieved in the tumor cell short time, rapid amplifying becomes class device
Official.The technology that this substep is cultivated makes primary cell can quickly form organoid, and obtains enough within the time effectively
Many cells carry out subsequent experimental operation.Esophageal carcinoma primary cell is realized ECRM-I, ECRM-II, ECRM-of rapid amplifying
III culture medium and the EDM-1 culture medium used when amplification culture and drug susceptibility-types detect are used in combination.
In tumor organoid incubation, tumor metabolic is vigorous, can produce oxygen-derived free radicals and to cell damage, fall
Low cell viability, causes differentiation, apoptosis.The esophageal carcinoma of the present invention primary organoid culture fluid with the addition of antioxidant, gluathione
Peptide or vitamin C or vitamin E are all the natural metabolism products of the most retrievable material of cell or cell, Ke Yiwei
Hold environment and intracellular oxidative pressure balance, scavenging activated oxygen, there is the effect of protection cell membrane integrity.β-sulfydryl second
Alcohol is also additive common in cell cultivation, particularly stem cell incubation.Research shows, the shortage of antioxidant will make
The cell reactive enhancing to oxidative pressure, makes organoid vigor decline, and the most aging, functional rehabilitation postpones.Long-term cultivation
The problems such as esophageal carcinoma organoid has the more fragment of a certain proportion of appearance, occurs vesicle in cell, the speed of growth substantially reduction.
Antioxidant can improve the vigor of cell, reduces and produces aging ratio.
The present invention can improve the speed of growth of organoid, by shortening to for 1 to 2 week 2 to 6 original weeks.
The present invention improves the success rate that organoid is cultivated, and the tumor specimen of excision improves to more than 80%.
The present invention passes through formula and the using method of optimizing tissue Digestive system, obtains enough cultivations from small specimen
Tumor cell alive so that the biopsy specimen originally cannot cultivated is possibly realized.
The present invention is passed on and frozen formula and technology by optimization so that organoid keeps good after passing on and recovering
Vigor.
In the present invention, optimize the concentration of glucose under some specified conditions, match, by adding antioxidation freely
Base reagent, reduces the cell ageing caused in long-term cultivation.
Accompanying drawing explanation
Fig. 1 is the statistical result that several additives formula In vitro culture forms organoid rate number.
Wherein, culture medium culturing based on B, BW be on the basis of basal medium add Wnt3a cultivate, B27 be
Adding B27 additive on the basis of basal medium to cultivate, BM is to add BMP4 on the basis of basal medium to cultivate, and BE is
Adding EGF on the basis of basal medium to cultivate, BF is to add FGF2 on the basis of basal medium to cultivate, and BH is at base
Adding HGF on the basis of basal culture medium to cultivate, BEW is to add Wnt3a and EGF on the basis of basal medium to cultivate, EDM-
I, ECRM-I, ECRM-II, ECRM-III are respectively corresponding culture medium culturing.
Detailed description of the invention
For being best understood from the present invention, below in conjunction with embodiment and accompanying drawing, the invention will be further described, following example
It is only that the present invention will be described rather than is limited it.
The preparation of embodiment one special culture media
Culture medium of the present invention includes
One or more receptor tyrosine kinase parts: include the epithelical cell growth factor of human or animal, concentration range
At 2ng/mL to 100ng/mL；Human or animal's hepatocyte growth factor, concentration range is at 10ng/mL to 200ng/mL；People or dynamic
Thing basic fibroblast growth factor, concentration range is 5ng/mL to 100ng/mL；
The FZ inhibitors of kinases that Rho is relevant: selected from Fasudil, Y-27632, RKI-1447 and GSK429286A；
Multivitamin and hormone: putrescine, concentration range is at 0.1 μ g/mL to 100 μ g/mL；Adrenalone, concentration range
At 10ng/mL to 10 μ g/mL；Nicotiamide, concentration range is at 1 μ g/mL to 2mg/mL；Vitamin A acetate, concentration range exists
10ng/mL to 500ng/mL；
Antioxidant: selected from reduced glutathion；Vitamin C；Vitamin E；(0.01mM is extremely for beta-mercaptoethanol
1.5mM)；
The agonist of the path of suppression cell differentiation: people's activin A albumen, concentration range is 5n/mL to 200ng/mL；
Wnt pathway agonist, including the Wnt3a albumen of restructuring human or animal, human or animal's RSPO-1 albumen of recombinating；GSK-3 β suppresses
Agent, selected from CHIR-99021 (No. CAS: 252917-06-9), SB216763 (No. CAS: 280744-09-4) etc.；Hedgehog leads to
Road agonist, including restructuring human or animal SHH (Sonic hedgehog) albumen, the agonist SAG of SMO albumen (No. CAS:
912545-86-9)。
Embodiment two esophageal carcinoma primary cell realize rapid amplifying ECRM-I, ECRM-II, ECRM-III culture medium and
The preparation of the EDM-1 culture medium used when amplification culture and drug susceptibility-types detect
The formula of ECRM-I includes DMEM/F12 culture medium, adds 2.5%FBS, 1x B27 additive, ascorbic acid, dimension
Raw element A acetate, Adrenalone, putrescine, nicotiamide, insulin, hydrocortisone, people's activin A, FGF2, Wnt3a, EGF,
Tretinoin and Y27632.
The formula of ECRM-II culture medium includes DMEM/F12 culture medium, adds 2.5%FBS, 1x B27 additive, nicotinoyl
Amine, Adrenalone, BMP4, EGF, Wnt3a, IGF, sodium butyrate, putrescine, vitamin A acetate, insulin, dexamethasone, β-mercapto
Base ethanol, FGF2, people's activin A, tretinoin and Y27632.
The formula of ECRM-III culture medium includes DMEM/F12 culture medium, adds 1%BSA, 1x B27 additive, peroxidating
Hydrogen is mould, vitamin A acetate, nicotiamide, Adrenalone, sodium butyrate, insulin, dexamethasone, putrescine, reduced form gluathione
Peptide, people's activin A, EGF, BMP4, FGF1, NOG, SAG, RSPO1, Wnt3a and Y27632.
EDM-I culture medium prescription include in DMEM/F12 culture medium add 2.5%FBS, B27 additive, HGF, IGF,
Wnt3a, EGF, people's activin A, Adrenalone, vitamin A acetate, nicotiamide, insulin, reduced glutathion.
The preparation of embodiment three tissue digestion liquid
Optimize operation and biopsy Digestive system, the maximum acquisition rate in the case of holding tumor vigor can be realized.
EM-BS-1 organizes the formula of enzymolysis solution as follows: add 2.5%FBS, IX Collagen Type VI (1 μ g/ in DMEM culture medium
ML-10 μ g/mL), neutral proteolytic enzyme (50 μ g/mL-500 μ g/mL).
EM-BS-2 organizes the formula of enzymolysis solution as follows: add 2.5%FBS, 1x penicillin and strepto-in DMEM culture medium
Element, IV Collagenase Type (0.01mg/mL-1mg/mL), hyaluronidase (0.001mg/mL-0.2mg/mL) and DNA enzymatic I
(0.001mg/mL-0.2mg/mL)。
The formula of EM-3 enzymolysis solution is as follows: add 2.5%FBS, 1x penicillin and streptomycin, XI type glue in DMEM culture medium
Protoenzyme (20U/mL-200U/mL), Bacillus polymyxa Neutral proteinase neutral proteolytic enzyme I (1 μ g/mL-100 μ g/mL) and DNA enzymatic I (0.01mg/
mL-1mg/mL)。
The cultural method of embodiment four esophageal carcinoma tumor organoid
The present invention obtains specifically comprising the following steps that of process human esophageal carcinoma and (is wrapped by the esophageal carcinoma specimen tissue of fresh acquisition
Include the human esophageal carcinoma obtained in excision tissue, biopsy or PDX model), clean with tissue-wash solution, clean three times
After be transferred to tissue transfer liquid in, be placed in 0 to 4 degrees Celsius transfer or short-term preservation.It is organized in the cell of air cleaner
In culturing room, operation in more than two grades Biohazard Safety Equipments.To bigger surgical tissue, the doctor containing 70%～75% ethanol
Soak tissue 10 seconds with in disinfectant solution, take out and be placed in PBS, clean 3 times, remove residual ethanol, transfer to steril cell training
Support in ware, sop up surplus liquid, with sterilization eye scissors place to go connective tissue, select knub position harder, that color is white, take 10mm and see
Side's left and right tumor tissues.Add 0.5mL tissue digestion liquid, repeatedly shred tissue more than 50 times with sterilizing eye scissors, cut into 1mm
Square fritter, can suck smoothly to 1mL pipettor gun head.The tissue shredded is transferred to, in sterile centrifugation tube, continuously add 2
～10mL enzymolysis solution, clean the tumor tissues in transfer culture dish, be incorporated in centrifuge tube.It is placed in 37 degrees Celsius of shaking tables digestion,
Frequently take out observation, digestion to how with widow's cell mass or unicellular.Through 70 μm cell screen clothes, filtered solution transfers to 50mL
In centrifuge tube, adding 20mL PBS, 200g and be centrifuged 3 minutes, abandon supernatant, resuspended with 20mL PBS, 200g is centrifuged 3 minutes again.
Suck supernatant carefully, add the 5mL esophageal carcinoma of the present invention organoid and cultivate special culture solution, re-suspended cell.Take 100 μ L thin
Born of the same parents' suspension adds trypan blue, calculates the quantity of living cells by platelet counter.
The cultivation stage concrete operation step of esophageal cancer cell organoid of the present invention: human esophageal carcinoma is through mechanical shear
Cut with enzymic digestion after, it is thus achieved that unicellular and few cell mass suspension, with culture medium resuspended adjustment cell density after counting, the body such as addition
Long-pending 4 DEG C of Matrigel mixing thawed, in certain embodiments, Marigel adds volume and is adjusted to 0.1 times of cell suspension
To 1 times.After cell suspension is resuspended with Matrigel, it is inoculated in 24 orifice plates, is placed in 37 DEG C of cell culture incubators, after 20 minutes, treats
Matrigel solidifies, and adds culture medium, changes liquid every other day.After 4-10 days, esophageal carcinoma organoid grows up to many spheroid forms, has Epithelial
Cellular layer.
Esophageal carcinoma primary cell collection of specimens is the successful committed step of primitive cell culture, and collection of specimens and transport are not
When, it will directly affecting the success or not of tumor organoid, basic demand and the points for attention of tumor specimen collection are described below:
(1) prevention and control antibacterial and fungal contamination.Operation technique environment not sterile working, environment and internal have a lot of microorganism, correctly
Collection and processing mode can reduce pollution to greatest extent.Preparation tissue-wash solution: normal saline (0.9% sodium chloride) or
Person's phosphate buffer (PBS) adds penicillin (500U/mL), amphotericin B (2.5 μ g/mL) and streptomycin (500 μ g/
ML), filtration sterilization.Preparation tissue transfer liquid: add 5% hyclone in DMEM culture medium, add penicillin (500U/mL),
Amphotericin B (2.5 μ g/mL) and streptomycin (500 μ g/mL).After the apparatus autoclavings such as the shears drawn materials, tweezers, blade
Dry.(2) collection of specimens to choose peplos completely as far as possible, eugonic region, it is to avoid rot tissue, slough, fat
And connective tissue.Structural blood, fat, slough and connective tissue is carefully removed during pretreatment.(3) operation transport
Process will as quickly as possible, and the time after organizing in vitro is the most long, and the success rate of external structure tumor organoid is the lowest, typically after in vitro
Complete in 4 hours to cultivate operation.If desired, specimen can store by 4 C overnight in specimen transfer liquid, but can be substantially reduced
Success rate, increases and pollutes probability.
The substep culture technique dedifferented by condition, it is achieved in the tumor cell short time, rapid amplifying becomes organoid.This
The technology that one substep is cultivated makes primary cell can quickly form organoid, and obtains abundant thin within the time effectively
Born of the same parents carry out subsequent experimental operation.In some embodiments, the unicellular or few cell prepared from acquisition operation or biopsy specimen
Use ECRM-I, ECRM-II, ECRM-III culture medium culturing cell, it is achieved the part of tumor cell is dedifferented and rapid amplifying,
This process was at 3-10 days.Such as 0-7 day, 0-6 day, 0-5 day, 0-4 day, 0-3 day, 0-2 day, 0-
1,0th be wherein that day that cell separates from its derived tissues, and the 1st is that day subsequently, or uses EDM-I
Culture medium culturing cell 1 week or more long, such as 2,3,4 weeks or more long, or 1,2,3,4,5,6,7,8,9,10,11,12 months
Or it is more long.In some embodiments, EDM-I culture medium can use cultivate on the 1st, is using EDM-I culture medium
Under the conditions of, carry out tumor organoid biology or the experiment of drug effect.
Embodiment five tests the impact on organoid In vitro culture formation rate of the several additives formula
2.5%FBS, Adrenalone, nicotiamide, ascorbic acid and antibiotic is added as base in DMEM/F12 culture medium
Basal culture medium (B), adds Wnt3a (BW) the most respectively, adds B27 additive (B27), interpolation BMP4 (BM), interpolation
EGF (BE), interpolation FGF2 (BF), interpolation HGF (BH), interpolation Wnt3a and EGF (BEW).In addition with as described above
ECRM-I, ECRM-II, ECRM-III and EDM-I condition of culture.Under these culture conditions, test P1 is for the formation of organoid
Rate, the unicellular 5x10 of P0 band organoid4It is layered on after mixing with matrigel in 24 moistening in advance orifice plates, static at 37 degrees Celsius
After 10 minutes, after matrigel solidifies, in different holes, add the above-mentioned culture medium of 1mL respectively.Respectively cultivate the 5th day and
The organoid number of record amplification in the 7th day.
As it is shown in figure 1, under ECRM-I, ECRM-II, ECRM-III and EDM-I condition of culture, hence it is evident that be better than B, BW, B27,
BM, BF, BH, BEW condition of culture, wherein the condition of culture best results of ECRM-II.
The above embodiment is only to be described the preferred embodiment of the present invention, the not model to the present invention
Enclose and be defined, on the premise of designing spirit without departing from the present invention, the those of ordinary skill in the art technical side to the present invention
Various deformation that case is made and improvement, all should fall in the protection domain that claims of the present invention determines.
Claims (10)
1. be used for a special culture media for In vitro culture esophageal carcinoma tumor organoid based on Human Esophageal Carcinoma, its feature exists
Following components is included in, described special culture media:
(1) receptor tyrosine kinase part；
(2) FZ inhibitors of kinases relevant for Rho；
(3) Metabolism, Vitamins and Hormones；
(4) antioxidant；
(5) agonist of the path of suppression cell differentiation；
Described receptor tyrosine kinase part includes the epithelical cell growth factor of human or animal, human or animal's hepatocyte growth factor
One or more in son and human or animal's basic fibroblast growth factor；
The concentration range of the epithelical cell growth factor of human or animal is 2ng/mL～100ng/mL；
The concentration range of human or animal's hepatocyte growth factor is 10ng/mL～200ng/mL；
The concentration range of human or animal's basic fibroblast growth factor is 5ng/mL～100ng/mL；
FZ inhibitors of kinases relevant for described Rho includes in Fasudil, Y-27632, RKI-1447 and GSK429286A
One or more.
The most according to claim 1 a kind of based on Human Esophageal Carcinoma special for In vitro culture esophageal carcinoma tumor organoid
By culture medium, it is characterised in that: described Metabolism, Vitamins and Hormones includes in putrescine, Adrenalone, nicotiamide and vitamin A acetate
One or more.
The most according to claim 2 a kind of based on Human Esophageal Carcinoma special for In vitro culture esophageal carcinoma tumor organoid
By culture medium, it is characterised in that: described
The concentration range of putrescine is 0.1 μ g/mL～100 μ g/mL；
The concentration range of Adrenalone is 10ng/mL～10 μ g/mL；
The concentration range of nicotiamide is 1 μ g/mL～2mg/mL；
The concentration range of vitamin A acetate is at 10ng/mL～500ng/mL.
The most according to claim 1 a kind of based on Human Esophageal Carcinoma special for In vitro culture esophageal carcinoma tumor organoid
By culture medium, it is characterised in that: described antioxidant includes reduced glutathion, vitamin C, vitamin E and β-sulfydryl second
One or more in alcohol.
The most according to claim 4 a kind of based on Human Esophageal Carcinoma special for In vitro culture esophageal carcinoma tumor organoid
By culture medium, it is characterised in that: the concentration range of described beta-mercaptoethanol is 0.01mM～1.5mM.
The most according to claim 1 a kind of based on Human Esophageal Carcinoma special for In vitro culture esophageal carcinoma tumor organoid
By culture medium, it is characterised in that: the agonist of the path of described suppression cell differentiation includes that people's activin A albumen, Wnt path swash
One or more in dynamic agent, Hedgehog pathway agonist.
The most according to claim 6 a kind of based on Human Esophageal Carcinoma special for In vitro culture esophageal carcinoma tumor organoid
By culture medium, it is characterised in that: described
The concentration range of people's activin A albumen is 5ng/mL～200ng/mL；
Wnt pathway agonist includes that the Wnt3a albumen of restructuring human or animal, restructuring human or animal's RSPO-1 albumen, GSK-3 β press down
One or more in preparation；
Hedgehog pathway agonist includes human or animal's SHH albumen of recombinating, the one or many in the agonist SAG of SMO albumen
Kind.
The most according to claim 1 a kind of based on Human Esophageal Carcinoma special for In vitro culture esophageal carcinoma tumor organoid
By culture medium, it is characterised in that described special culture media includes following components:
DMEM/F12 culture medium, adds on 2.5% hyclone, 1xB27 additive, ascorbic acid, vitamin A acetate, kidney
Gland ketone, putrescine, nicotiamide, insulin, hydrocortisone, people's activin A, FGF2, Wnt3a, EGF, tretinoin and Y27632；Or
Person
DMEM/F12 culture medium, add 2.5% hyclone, 1xB27 additive, nicotiamide, Adrenalone, BMP4, EGF,
Wnt3a, IGF, sodium butyrate, putrescine, vitamin A acetate, insulin, dexamethasone, beta-mercaptoethanol, FGF2, people's activin
A, tretinoin and Y27632；Or
DMEM/F12 culture medium, add that 1% bovine serum albumin, 1xB27 additive, hydrogen peroxide be mould, vitamin A acetate,
Nicotiamide, Adrenalone, sodium butyrate, insulin, dexamethasone, putrescine, reduced glutathion, people's activin A, EGF,
BMP4, FGF1, NOG, SAG, RSPO1, Wnt3a and Y27632；Or
DMEM/F12 culture medium, add 2.5% hyclone, 1xB27 additive, HGF, IGF, Wnt3a, EGF, people's activin A,
Adrenalone, vitamin A acetate, nicotiamide, insulin, reduced glutathion.
9. one kind utilize claim 1～8 arbitrary described based on Human Esophageal Carcinoma for In vitro culture esophageal carcinoma tumor class
The cultural method of the special culture media of organ, it is characterised in that comprise the following steps:
(1) by the esophageal carcinoma specimen tissue of fresh acquisition, clean with tissue-wash solution；
(2) once purged esophageal carcinoma specimen tissue is transferred in tissue transfer liquid, is placed in 0 to 4 degrees Celsius of transfers or short-term is protected
Deposit；
(3) from tissue transfer liquid, take out piece of tissue, in tissue-wash solution after rinsing, transfer in steril cell culture dish,
Sop up surplus liquid；
(4) according to the size of piece of tissue, add tissue digestion liquid, cut with sterilizing and repeatedly shred tissue；
(5) tissue shredded is transferred in sterile centrifugation tube, continuously add 2～10mL tissue digestion liquid, clean transfer and cultivate
Tumor tissues in ware, is incorporated in sterile centrifugation tube；
(6) sterile centrifugation tube being placed in 37 degrees Celsius of shaking tables digestion, frequently take out observation, how digestion is to few cell mass or list
Till cell；
(7) by the suspension in sterile centrifugation tube through 70 μm cell screen clothes, filtered solution is transferred in 50mL centrifuge tube；
(8) adding 10～30mL PBS in 50mL centrifuge tube, 100～300g are centrifuged 2～5 minutes, abandon supernatant, with 10～30mL
PBS is resuspended, again 100～300g is centrifuged 2～5 minutes；
(9) suck the supernatant in centrifuge tube carefully, add the special culture media of 3～8mL esophageal carcinoma tumor organoids, resuspended
Cell；
(10) take 50～200 μ L cell suspension and add trypan blue, calculate the quantity of living cells by platelet counter；
(11) special culture media of the cell suspension esophageal carcinoma tumor organoid after counting carries out resuspended adjustment cell density, adds
Enter the Matrigel of 4 DEG C of defrostings of cell suspension 0.1 to 1 times；
(12), after cell suspension is resuspended with Matrigel, it is inoculated in 24 orifice plates, is placed in 37 DEG C of cell culture incubators, 15～30 minutes
After, treat that Matrigel solidifies, add the special culture media of esophageal carcinoma tumor organoid, change liquid every other day；
After (13) 4～10 days, esophageal carcinoma organoid grows up to many spheroid forms, has epithelioid cell layer.
The most according to claim 9 a kind of based on Human Esophageal Carcinoma for In vitro culture esophageal carcinoma tumor organoid
The cultural method of special culture media, it is characterised in that the compound method of step (1) and (3) described tissue-wash solution is: at physiology
Saline or phosphate buffer add the penicillin of 500U/mL, the amphotericin B of 2.5 μ g/mL and the strepto-of 500 μ g/mL
Element, filtration sterilization；
The compound method of step (2) described tissue transfer liquid is: adds 5% hyclone in DMEM culture medium, adds
The penicillin of 500U/mL, the amphotericin B of 2.5 μ g/mL and the streptomycin of 500 μ g/mL；
The compound method of step (4) and (5) described tissue digestion liquid is:
2.5% hyclone, 1 μ g/mL～the IX Collagen Type VI of 10 μ g/mL, 50 μ g/mL-500 μ g/ are added in DMEM culture medium
The neutral proteolytic enzyme of mL；Or
DMEM culture medium adds the IV Collagen Type VI of 2.5% hyclone, 1x penicillin and streptomycin, 0.01mg/mL-1mg/mL
Enzyme, the hyaluronidase of 0.001mg/mL～0.2mg/mL and DNA enzymatic I of 0.001mg/mL～0.2mg/mL；Or
DMEM culture medium adds the XI Collagen Type VI of 2.5% hyclone, 1x penicillin and streptomycin, 20U/mL～200U/mL
DNA enzymatic I of Bacillus polymyxa Neutral proteinase neutral proteolytic enzyme I and 0.01mg/mL～1mg/mL of enzyme, 1 μ g/mL～100 μ g/mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610548084.1A CN106190980A (en) | 2016-07-12 | 2016-07-12 | A kind of special culture media and cultural method being used for In vitro culture esophageal carcinoma tumor organoid based on Human Esophageal Carcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610548084.1A CN106190980A (en) | 2016-07-12 | 2016-07-12 | A kind of special culture media and cultural method being used for In vitro culture esophageal carcinoma tumor organoid based on Human Esophageal Carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106190980A true CN106190980A (en) | 2016-12-07 |
Family
ID=57477242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610548084.1A Pending CN106190980A (en) | 2016-07-12 | 2016-07-12 | A kind of special culture media and cultural method being used for In vitro culture esophageal carcinoma tumor organoid based on Human Esophageal Carcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106190980A (en) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107041361A (en) * | 2017-04-20 | 2017-08-15 | 北京奥康华医学检验所有限公司 | The store method and preservation reagent of a kind of tumor tissues |
| CN107151645A (en) * | 2017-05-16 | 2017-09-12 | 武汉大学深圳研究院 | A kind of method and culture medium that in vitro individuation drug test is provided for lung cancer |
| CN109554345A (en) * | 2018-11-21 | 2019-04-02 | 新格元(南京)生物科技有限公司 | A kind of digestive juice and its method that Tissues of Human Adenocarcinoma of Pancreas is separated into single living cell |
| CN109609440A (en) * | 2018-12-29 | 2019-04-12 | 上海烈冰生物医药科技有限公司 | The dissociation kit and method of single cell suspension are prepared for people's gastric tissue |
| CN109837242A (en) * | 2019-03-21 | 2019-06-04 | 陕西茵莱生物科技有限公司 | A kind of cultural method of the foreign bodies for scientific experiment |
| CN110090300A (en) * | 2018-01-29 | 2019-08-06 | 中国科学院动物研究所 | A kind of method and its application for the Regeneration and Repair promoting histoorgan |
| CN110656086A (en) * | 2019-10-11 | 2020-01-07 | 纳肽得(青岛)生物医药有限公司 | In vitro culture method of cancer organoid |
| WO2019238143A3 (en) * | 2018-06-13 | 2020-01-30 | 北京吉尚立德生物科技有限公司 | Colorectal cancer solid tumour primary cell and colorectal cancer ascitic fluid primary tumour cell culturing method, and matching reagent |
| CN110777116A (en) * | 2019-10-11 | 2020-02-11 | 纳肽得有限公司 | Tumor sample pretreatment method |
| CN110878286A (en) * | 2019-12-24 | 2020-03-13 | 江苏信安佳医疗科技有限公司 | Culture medium for culturing liver cancer organoid cell balls |
| CN111411084A (en) * | 2020-04-28 | 2020-07-14 | 江苏信安佳医疗科技有限公司 | Culture medium and culture method for constructing liver tumor stent-free organoid |
| CN112501119A (en) * | 2020-11-13 | 2021-03-16 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院中山大学肿瘤研究所) | Pituitary adenoma organoid culture medium and application thereof |
| CN112608899A (en) * | 2020-11-23 | 2021-04-06 | 广州市达瑞生物技术股份有限公司 | Application of serum-free medium in culturing cancer tissue-originated spheroids |
| CN113249325A (en) * | 2020-02-11 | 2021-08-13 | 合肥中科普瑞昇生物医药科技有限公司 | Culture medium and culture method of esophageal squamous carcinoma primary cells |
| CN113528444A (en) * | 2020-04-15 | 2021-10-22 | 合肥中科普瑞昇生物医药科技有限公司 | Culture medium for esophageal squamous carcinoma epithelial cells, culture method and application of culture medium |
| CN113943755A (en) * | 2020-07-15 | 2022-01-18 | 四川大学华西医院 | Method for constructing in-situ primary esophageal cancer animal model |
| CN114231490A (en) * | 2021-12-23 | 2022-03-25 | 北京基石生命科技有限公司 | Method for culturing tumor organoid by permeable hydrogel scaffold |
| CN114586768A (en) * | 2020-12-03 | 2022-06-07 | 江苏齐氏生物科技有限公司 | Liver tissue preservation solution and preservation method and application thereof |
| CN114736865A (en) * | 2022-03-09 | 2022-07-12 | 上海交通大学医学院附属第九人民医院 | Salivary gland malignant polymorphic adenoma 3D organoid and culture method and application thereof |
| CN114807039A (en) * | 2022-06-22 | 2022-07-29 | 杭州艾名医学科技有限公司 | Culture medium and culture method for esophageal cancer tumor organoid culture |
| US11622964B2 (en) | 2018-01-29 | 2023-04-11 | Institute Of Zoology, Chinese Academy Of Sciences | Method for destroying cellular mechanical homeostasis and promoting regeneration and repair of tissues and organs, and use thereof |
| WO2023060709A1 (en) * | 2021-10-14 | 2023-04-20 | 合肥中科普瑞昇生物医药科技有限公司 | Esophageal cancer organoid culture medium and culture method and use thereof |
| WO2024065883A1 (en) * | 2022-09-28 | 2024-04-04 | 合肥中科普瑞昇生物医药科技有限公司 | Culture medium for nasopharyngeal carcinoma organoid culture, and culture method and use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102439135A (en) * | 2009-02-03 | 2012-05-02 | 荷兰皇家科学院 | Culture medium for epithelial stem cells and organoids comprising said stem cells |
| CN104024401A (en) * | 2011-06-10 | 2014-09-03 | 荷兰皇家科学院 | Culture media for stem cells |
| WO2015173425A1 (en) * | 2014-05-16 | 2015-11-19 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved culture method for organoids |
| CN105695394A (en) * | 2016-04-07 | 2016-06-22 | 中山大学 | In vitro culture method of mouse salivary gland organ |
-
2016
- 2016-07-12 CN CN201610548084.1A patent/CN106190980A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102439135A (en) * | 2009-02-03 | 2012-05-02 | 荷兰皇家科学院 | Culture medium for epithelial stem cells and organoids comprising said stem cells |
| CN104024401A (en) * | 2011-06-10 | 2014-09-03 | 荷兰皇家科学院 | Culture media for stem cells |
| WO2015173425A1 (en) * | 2014-05-16 | 2015-11-19 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved culture method for organoids |
| CN105695394A (en) * | 2016-04-07 | 2016-06-22 | 中山大学 | In vitro culture method of mouse salivary gland organ |
Cited By (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107041361A (en) * | 2017-04-20 | 2017-08-15 | 北京奥康华医学检验所有限公司 | The store method and preservation reagent of a kind of tumor tissues |
| CN107151645A (en) * | 2017-05-16 | 2017-09-12 | 武汉大学深圳研究院 | A kind of method and culture medium that in vitro individuation drug test is provided for lung cancer |
| US11622964B2 (en) | 2018-01-29 | 2023-04-11 | Institute Of Zoology, Chinese Academy Of Sciences | Method for destroying cellular mechanical homeostasis and promoting regeneration and repair of tissues and organs, and use thereof |
| CN110090300A (en) * | 2018-01-29 | 2019-08-06 | 中国科学院动物研究所 | A kind of method and its application for the Regeneration and Repair promoting histoorgan |
| WO2019238143A3 (en) * | 2018-06-13 | 2020-01-30 | 北京吉尚立德生物科技有限公司 | Colorectal cancer solid tumour primary cell and colorectal cancer ascitic fluid primary tumour cell culturing method, and matching reagent |
| CN109554345A (en) * | 2018-11-21 | 2019-04-02 | 新格元(南京)生物科技有限公司 | A kind of digestive juice and its method that Tissues of Human Adenocarcinoma of Pancreas is separated into single living cell |
| CN109609440A (en) * | 2018-12-29 | 2019-04-12 | 上海烈冰生物医药科技有限公司 | The dissociation kit and method of single cell suspension are prepared for people's gastric tissue |
| CN109837242A (en) * | 2019-03-21 | 2019-06-04 | 陕西茵莱生物科技有限公司 | A kind of cultural method of the foreign bodies for scientific experiment |
| CN110656086A (en) * | 2019-10-11 | 2020-01-07 | 纳肽得(青岛)生物医药有限公司 | In vitro culture method of cancer organoid |
| CN110777116A (en) * | 2019-10-11 | 2020-02-11 | 纳肽得有限公司 | Tumor sample pretreatment method |
| CN110656086B (en) * | 2019-10-11 | 2021-06-29 | 纳肽得(青岛)生物医药有限公司 | In vitro culture method of cancer organoid |
| CN110878286A (en) * | 2019-12-24 | 2020-03-13 | 江苏信安佳医疗科技有限公司 | Culture medium for culturing liver cancer organoid cell balls |
| CN110878286B (en) * | 2019-12-24 | 2023-07-18 | 江苏信安佳医疗科技有限公司 | Culture medium for culturing liver cancer organoid cell balls |
| JP2023513267A (en) * | 2020-02-11 | 2023-03-30 | 合肥中科普瑞昇生物医▲薬▼科技有限公司 | Culture medium for primary cells of esophageal squamous cell carcinoma, and culture method thereof |
| CN113249325B (en) * | 2020-02-11 | 2023-02-17 | 合肥中科普瑞昇生物医药科技有限公司 | Culture medium and culture method of esophageal squamous carcinoma primary cells |
| WO2021159560A1 (en) * | 2020-02-11 | 2021-08-19 | 合肥中科普瑞昇生物医药科技有限公司 | Culture medium for primary cells of esophageal squamous carcinoma, and cultivation method therefor |
| JP7454290B2 (en) | 2020-02-11 | 2024-03-22 | 合肥中科普瑞昇生物医▲薬▼科技有限公司 | Culture medium for primary cells of esophageal squamous cell carcinoma and method for culturing the same |
| CN113249325A (en) * | 2020-02-11 | 2021-08-13 | 合肥中科普瑞昇生物医药科技有限公司 | Culture medium and culture method of esophageal squamous carcinoma primary cells |
| CN113528444A (en) * | 2020-04-15 | 2021-10-22 | 合肥中科普瑞昇生物医药科技有限公司 | Culture medium for esophageal squamous carcinoma epithelial cells, culture method and application of culture medium |
| CN111411084A (en) * | 2020-04-28 | 2020-07-14 | 江苏信安佳医疗科技有限公司 | Culture medium and culture method for constructing liver tumor stent-free organoid |
| CN113943755A (en) * | 2020-07-15 | 2022-01-18 | 四川大学华西医院 | Method for constructing in-situ primary esophageal cancer animal model |
| CN113943755B (en) * | 2020-07-15 | 2023-09-12 | 四川大学华西医院 | Method for constructing in-situ primary esophageal cancer animal model |
| CN112501119A (en) * | 2020-11-13 | 2021-03-16 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院中山大学肿瘤研究所) | Pituitary adenoma organoid culture medium and application thereof |
| CN112501119B (en) * | 2020-11-13 | 2023-06-20 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院中山大学肿瘤研究所) | Pituitary adenoma organoid culture medium and application thereof |
| CN112608899B (en) * | 2020-11-23 | 2024-02-27 | 广州市达瑞生物技术股份有限公司 | Application of serum-free culture medium in culturing spheroids of cancer tissue origin |
| CN112608899A (en) * | 2020-11-23 | 2021-04-06 | 广州市达瑞生物技术股份有限公司 | Application of serum-free medium in culturing cancer tissue-originated spheroids |
| CN114586768A (en) * | 2020-12-03 | 2022-06-07 | 江苏齐氏生物科技有限公司 | Liver tissue preservation solution and preservation method and application thereof |
| WO2023060709A1 (en) * | 2021-10-14 | 2023-04-20 | 合肥中科普瑞昇生物医药科技有限公司 | Esophageal cancer organoid culture medium and culture method and use thereof |
| CN114231490A (en) * | 2021-12-23 | 2022-03-25 | 北京基石生命科技有限公司 | Method for culturing tumor organoid by permeable hydrogel scaffold |
| CN114736865A (en) * | 2022-03-09 | 2022-07-12 | 上海交通大学医学院附属第九人民医院 | Salivary gland malignant polymorphic adenoma 3D organoid and culture method and application thereof |
| CN114807039B (en) * | 2022-06-22 | 2022-10-04 | 杭州艾名医学科技有限公司 | Culture medium and culture method for esophageal cancer tumor organoid culture |
| CN114807039A (en) * | 2022-06-22 | 2022-07-29 | 杭州艾名医学科技有限公司 | Culture medium and culture method for esophageal cancer tumor organoid culture |
| WO2024065883A1 (en) * | 2022-09-28 | 2024-04-04 | 合肥中科普瑞昇生物医药科技有限公司 | Culture medium for nasopharyngeal carcinoma organoid culture, and culture method and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106190980A (en) | A kind of special culture media and cultural method being used for In vitro culture esophageal carcinoma tumor organoid based on Human Esophageal Carcinoma | |
| Pors et al. | Initial steps in reconstruction of the human ovary: survival of pre-antral stage follicles in a decellularized human ovarian scaffold | |
| Sato et al. | In vitro sperm production from mouse spermatogonial stem cell lines using an organ culture method | |
| Peh et al. | Human corneal endothelial cell expansion for corneal endothelium transplantation: an overview | |
| CN104560870B (en) | A kind of method for preparing decidua mescenchymal stem cell | |
| Lerer-Serfaty et al. | Attempted application of bioengineered/biosynthetic supporting matrices with phosphatidylinositol-trisphosphate-enhancing substances to organ culture of human primordial follicles | |
| Neng et al. | Isolation and culture of endothelial cells, pericytes and perivascular resident macrophage-like melanocytes from the young mouse ear | |
| CN112841168B (en) | Tissue preservation solution and application thereof | |
| CN105076114A (en) | Serum-free preservation liquid for umbilical cord mesenchymal stem cells and application of serum-free preservation liquid | |
| Ang et al. | Development of a conjunctival epithelial equivalent with improved proliferative properties using a multistep serum-free culture system | |
| Głabowski et al. | Growth factors effects on preimplantation development of mouse embryos exposed to tumor necrosis factor alpha | |
| Baylis et al. | An investigation of donor and culture parameters which influence epithelial outgrowths from cultured human cadaveric limbal explants | |
| Proietto et al. | Development and assessment of a novel canine ex vivo corneal model | |
| Garcin et al. | Three-month storage of human corneas in an active storage machine | |
| CN106520679A (en) | Kit for culturing pancreas stem cells | |
| Toyoshima et al. | Regeneration of a bioengineered 3D integumentary organ system from iPS cells | |
| Monnickendam et al. | Amphibian organ culture | |
| CN106754657A (en) | A kind of serum free medium of monkey embryonic stem cell | |
| CN104399122B (en) | A kind of acellular matrix and preparation method thereof | |
| Massie et al. | Development of causative treatment strategies for lacrimal gland insufficiency by tissue engineering and cell therapy. Part 2: reconstruction of lacrimal gland tissue: what has been achieved so far and what are the remaining challenges? | |
| CN109294977A (en) | A kind of liver cancer patient source chick chorioallantoic membrane M-PDX model building method | |
| CN107129966A (en) | A kind of corneal epithelial cell nutrient solution containing serum | |
| Khavinson et al. | A method of creating a cell monolayer based on organotypic culture for screening of physiologically active substances | |
| CN107312745B (en) | Serum-free epithelial cell culture solution | |
| CN107338214A (en) | Fibroblast and its preparation method and application, cell juice and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination |